Jeena Sikho Lifecare Limited

Healthcare — Medical Care Facilities · NSE

₹389.70+₹1.00 (+0.26%)

DalalBaazaar Score

75 / 100

🟢 Good

Verdict

REASONABLE

Risk

Low

Driven by micro-cap size, which brings thin liquidity.

In simple words: Strong business and financial position, with both sales and profits growing well. Nothing on this snapshot stands out as an immediate concern — the usual checks on business quality and management still apply.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:02 pm

Mixed / neutral. No major red flags jump out, but nothing here screams "obviously cheap" either. This is a name that needs a peer comparison and a view on near-term earnings triggers before sizing a position.

Understanding the Business

Company site ↗

The 60-second version of Jeena Sikho Lifecare Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Jeena Sikho Lifecare Limited trades in ayurvedic products in India and internationally. It operates through Ayurvedic products/medicine, Ayurvedic healthcare services, and others segments. The company offers ayurvedic products under the Shuddhi brand name.

IndustryMedical Care Facilities

SectorHealthcare

Employees4,299

Annual revenue₹799 Cr

How does it make money?

Turns over ₹799 Cr a year. Of every ₹100 of sales, about ₹28 reaches shareholders as profit, with ₹44 left at the operating level before interest, tax and depreciation. Each of its 4,299 employees supports ₹18.6 lakh of revenue a year, the signature of a people-led business.

EBITDA margin44.5%

Net margin27.8%

Revenue / employee₹18.6 lakh

Who are its competitors?

The closest listed comparisons in its industry are APOLLO HOSPITALS ENTER. L, SUN PHARMACEUTICAL IND L, CIPLA LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

APOLLO HOSPITALS ENTER. LP/E 54.3x · ROE 22.0%

SUN PHARMACEUTICAL IND LP/E 34.9x · ROE 14.5%

CIPLA LTDP/E 31.8x · ROE 9.8%

What is its competitive advantage?The numbers suggest a real one

ROCE has stayed above 15% in every year available and stands at 54.5%. Returns that high normally get competed away; when they persist, something is protecting them, and its ROE of 47.5% against a peer median of 14.5% is consistent with that. What that something is — brand, scale, switching costs, regulation — the accounts cannot tell you.

ROCE54.5%

ROE47.5%

Peer median ROE14.5%

What is the outlook?

1 analysts covering the stock expect revenue to grow about 35.8% and earnings to grow about 42.6% in the year to 2028. These are estimates by people who follow the company, not a forecast for the wider industry.

Est. revenue growth+35.8%

Est. earnings growth+42.6%

Analysts1

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +292% while net margin moved +68% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+292%

Margin effect+68%

DalalBaazaar Score

75/ 100

Good

Weighted across six categories. Every point is explained below.

• Beta of 1.04 — moves roughly with the market
✗ Micro Cap: thinner liquidity and sharper drawdowns are normal
✗ Profits have swung sharply from year to year — earnings are hard to forecast

Quality vs. Valuation

Company Quality

83/ 100

Excellent

How good the business is, ignoring the share price entirely.

Valuation

75/ 100

Cheap

What you are being asked to pay, ignoring how good the business is.

A good business currently available at an undemanding price — the combination this framework is built to look for.

Historical Valuation

Current P/E

20.5x

3Y Median

221.2x

40 monthly readings · mean 211.5x · range 21.8x–431.5x

Sector Median

34.9x

median of 3 sector peers

🟢Current valuation is approximately 91% below its 3y median of 221.2x. Cheaper than its own history, which is worth a reason too: the market may be pricing in something the backward-looking numbers do not show.

🟢Against its sector it trades 41% below the peer median of 34.9x.

vs. its own history

Cheap

221.2x median over 40 months · -91%

vs. sector peers

Cheap

34.9x median of 3 peers · -41%

vs. generic bands

Fair

15x–35x

P/E (Trailing)

20.5x

P/B

10.37x

EV/EBITDA

13.9x

PEG

0.23

Dividend Yield

1.15%

What's Good / What's Bad

🟢 What's Going Well8

Margins are improving
EBITDA margin is up from 24.9% to 44.5% over 3 years.
Cash flow has turned positive
Free cash flow moved from negative to positive over 3 years.
Return on equity is rising
ROE has improved from 26.8% to 47.5%.
Return on capital is rising
ROCE has improved from 35.7% to 54.5%.
High return on capital employed
ROCE of 54.5% is the mark of a business that converts capital into profit efficiently.
Valuation below its historical average
At 20.5x the stock trades 91% below its own median of 221.2x.
Very low debt
Debt/Equity of 0.27x leaves the balance sheet with plenty of headroom.
Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention2

Debt is rising
Total debt is up 15655% over 3 years — worth checking what it funded.
Inventory building faster than sales
Inventory is up 393% against revenue growth of 292% — stock may not be moving.

Red Flags

2 items require attention · 2 high

🔴Debt has risen sharplyFinancial
Total debt is up 15655% over 3 years, from ₹1 Cr to ₹127 Cr.
🔴Inventory building faster than salesFinancial
Inventory up 393% against revenue up 292% — stock may not be moving.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Capital compounds at a high rate
ROCE of 54.5% means each rupee reinvested earns well above what capital costs. If the company can keep deploying at this rate, growth creates value rather than just consuming cash.
Margin expansion has further to run
EBITDA margin has risen from 24.9% to 44.5%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.
Priced below its own history
The stock trades 91% below its own median multiple. If the business performs as it has and simply re-rates back to normal, that gap is return on its own.
Cheaper than its peers
It trades 41% below the sector median. Either the market sees a problem the numbers do not show, or the discount closes.
Self-funding with balance-sheet headroom
Positive free cash flow of ₹220 Cr alongside low debt means growth, buybacks or dividends need no outside money — and a downturn can be absorbed rather than refinanced.

🔴 Bear CaseWhat could go wrong?

Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
Several serious flags at once
2 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 43% a year✓ 57.7% CAGR
Latest reported year was 28.8%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 42%✓ 44.5%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Free cash flow remains positive✓ ₹220 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 0.4x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 51%✓ 54.5%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

11 / 12 checks passed

✓ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Analyst consensus isn't majority-sell
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

7 good · 3 neutral · 1 weak

Market Cap

₹4,845 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

20.5x

Fair

Fairly valued against the generic band

P/B Ratio

10.37x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

₹19

Profitable

Profitable on a per-share basis

ROE

47.5%

Strong

Strong capital efficiency

ROCE

54.5%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

0.27x

Low

Conservative leverage

Revenue Growth (YoY)

28.8%

Healthy

Healthy top-line growth

Profit Growth (YoY)

28.4%

Healthy

Profits growing at a healthy clip

Dividend Yield

1.15%

Modest

Small cash return — most of the return has to come from the price

Free Cash Flow

₹220 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

CMP

₹389.7

P/E (Forward)

10.9x

Improving

Below the trailing multiple — the street expects earnings to grow into the price

Operating Margin

34.2%

Good

Healthy core-business profitability

Net Margin

27.8%

Good

Strong bottom-line conversion

Current Ratio

3.25

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

1.04

Market-like

Moves roughly in line with the market

52W Range Position

Near low

Near its 52-week low

Technical Snapshot

SMA 20 / SMA 50

454.3 / 492.3

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

13.5

Oversold zone

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹204 Cr	₹324 Cr	₹469 Cr	₹799 Cr	+57.7%
EBITDA	₹51 Cr	₹97 Cr	₹145 Cr	₹356 Cr	+91.4%
EBITDA Margin	24.9%	30.0%	30.8%	44.5%	—
PAT (Net Profit)	₹34 Cr	₹69 Cr	₹80 Cr	₹222 Cr	+87.3%
EPS	₹2.74	₹5.57	₹6.42	₹17.81	+86.7%
ROE	26.8%	37.2%	31.2%	47.5%	—
ROCE	35.7%	39.7%	34.1%	54.5%	—
Total Debt	₹1 Cr	₹58 Cr	₹117 Cr	₹127 Cr	+440.1%
Free Cash Flow	-₹21 Cr	₹21 Cr	₹42 Cr	₹220 Cr	—

🟢 Revenue has grown at 57.7% a year over 3 years.

🟢 EBITDA has grown at 91.4% a year over 3 years.

🟢 EBITDA Margin has risen from 24.9% to 44.5% over 3 years (+19.6 pts).

🟢 PAT (Net Profit) has grown at 87.3% a year over 3 years.

🟢 EPS has grown at 86.7% a year over 3 years.

🟢 ROE has risen from 26.8% to 47.5% over 3 years (+20.7 pts).

🟢 ROCE has risen from 35.7% to 54.5% over 3 years (+18.8 pts).

🔴 Total Debt has grown at 440.1% a year over 3 years.

🟢 Free Cash Flow has turned positive, from -₹21 Cr to ₹220 Cr.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹674 Cr

Total Liabilities

₹207 Cr

Total Debt

₹127 Cr

Cash & Equivalents

₹16 Cr

Operating Cash Flow

₹254 Cr

Capex

-₹34 Cr

Shareholding (proxy)

Institutional Holding

0.3%

Insider Holding

72.5%

Corporate Actions

Dividend Rate

₹4.5

Ex-Dividend Date

21 Sept 2026

Analyst Consensus

Recommendations

1 Buy · 0 Hold · 0 Sell

Target Price (Mean)

₹1,000

+156.6% vs CMP

Target Range

₹1,000 – ₹1,000

Peer Comparison

Company	P/E	ROE
APOLLO HOSPITALS ENTER. L	54.3x	22.0%
SUN PHARMACEUTICAL IND L	34.9x	14.5%
CIPLA LTD	31.8x	9.8%

Recent News

1 positive2 mixed3 general

Is It Too Late To Consider Buying Jeena Sikho Lifecare Limited (NSE:JSLL)?

Simply Wall Street, 11 Aug

Jeena Sikho Lifecare Share Price Analysis

Kalkine India, 05 Oct

JSLL Share Price Falls 5.06% Amid Trading Valuation

Univest, 01 OctPrice move

🟡Mixed / dependsA price move rather than a change in the business. If the figures on this page have not moved, the fall is either an opportunity or news they have yet to catch up with.

Why Did Jeena Sikho Lifecare Shares Rally 54% in the Last 3 Trading Sessions? By Trade Brains

Investing.com India, 04 JunPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Jeena Sikho Lifecare revenue surges 29% in Q1FY27 on strong service demand

scanx.trade, 09 AugResults

🟢Potentially positiveReported improvement. Check whether it came from volume, price or a one-off item before treating it as a trend.

Choice reiterates 'Buy' on Jeena Sikho, sees 44% upside; stock rises 20%

Business Standard, 03 Jun

Watch Items

Trading very close to its 52-week low — worth checking whether this reflects a temporary setback or a structural problem.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
RSI is in oversold territory — could mean either a bargain or a stock still falling for good reason. Check the 'why' before assuming reversal.

DalalBaazaar Thesis

🟢Business QualityStrong17.9/20

🟢Financial HealthStrong15.6/20

🟢GrowthStrong14.9/20

🟢ProfitabilityStrong13.5/15

🟡ValuationFair9.1/15

🔴RiskHigh3.6/10

Attractive on both counts

A good business currently available at an undemanding price — the combination this framework exists to look for. The work left is qualitative: whether the advantage the numbers imply is one you can identify and expect to last. 2 high-severity red flags sit above this conclusion and should be read first.

This thesis breaks if

✓Revenue growth stays above 43% a year57.7% CAGR
✓EBITDA margin holds above 42%44.5%
✓Free cash flow remains positive₹220 Cr
✓Debt / EBITDA stays below 2x0.4x
✓ROCE stays above 51%54.5%